PFIZER’S CTI REQUESTS PROPOSALS FOR BIOTHERAPEUTIC TARGETS

Pre-Proposal Deadline: February 26, 2016

Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique program that collaborates with leading academic medical centers, the NIH, and foundations to speed the translation of novel targets to the clinic.

Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer’s technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

Foundations collaborating with CTI include:
- Alliance for Lupus Research
- Alzheimer’s Drug Discovery Foundation
- Crohn’s and Colitis Foundation of America
- Foundation for Sarcoidosis Research
- Juvenile Diabetes Research Foundation
- Jeffrey Modell Foundation

Pre-proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

For Questions

Please contact Venkat Reddy (Venkateshwar.reddy@pfizer.com) and Nathaniel Hafer (nathaniel.hafer@umassmed.edu)

What We Look For

- **Strong Project Rationale**: Demonstrated association between target biology and disease mechanism
- **Ability to Address Unmet Medical Needs**
- **Link between target pathway and human disease**
- **Feasibility**: tractable target, discovery/development plan
- **Novel drug targets** with potential to lead to differentiated drugs

Modalities

- **Large Molecules**: antibodies, proteins, peptides, ADCs, fusion proteins

Therapeutic Areas of Interest for Winter 2016

- **Oncology**: Immuno-oncology, epigenetic targets, novel tumor specific cell surface antigens, and targets identified by unique insights in tumor biology
- **Inflammation and Immune disorders**: Crohn’s and Colitis, Gastrointestinal disorders, and Rheumatoid Arthritis
- **Cardiovascular and metabolic diseases**: NAFLD/NASH and heart failure
- **Neuroscience**: neudegenerative disorders with a primary focus on Alzheimer's Disease and Parkinson’s Disease (non A beta therapies) and psychiatric symptom domains such as Cognition, Anxiety, and Motivation/Apathy
- **Rare monogenic genetic diseases**: Hematologic, neuromuscular, pulmonary, and inherited metabolic/endocrine diseases

All researchers and clinicians whose work meets these criteria are invited to apply. Please submit pre-proposals to Nate Hafer (nathaniel.hafer@umassmed.edu) by February 26, 2016.